Treatment of Hypertension With Ketanserin, a New Selective 5-Ht2 Receptor Antagonist.

BMJ
doi 10.1136/bmj.284.6315.537
Full Text
Abstract

Available in full text

Date
Authors
Publisher

BMJ

Related search

Ketanserin, a Novel 5-Hydroxytryptamine Antagonist: Monotherapy in Essential Hypertension.

British Journal of Clinical Pharmacology
Pharmacology
1983English

The Effects of a Selective 5-Ht2 Receptor Antagonist (ICI 170,809) on Platelet Aggregation and Pupillary Responses in Healthy Volunteers.

British Journal of Clinical Pharmacology
Pharmacology
1992English

The 5-Ht2 Antagonist Ketanserin Is an Open Channel Blocker of Human Cardiac Ether-À-Go-Go-Related Gene (hERG) Potassium Channels

British Journal of Pharmacology
Pharmacology
2009English

Robalzotan (NAD-299), a Novel Selective 5-Ht 1A Receptor Antagonist

CNS Drug Reviews
2006English

Azilsartan Medoxomil, an Angiotensin II Receptor Antagonist for the Treatment of Hypertension

Basic and Clinical Pharmacology and Toxicology
MedicineToxicologyPharmacology
2017English

AE9C90CB: A Novel, Bladder-Selective Muscarinic Receptor Antagonist for the Treatment of Overactive Bladder

British Journal of Pharmacology
Pharmacology
2010English

New Treatment Options for Pulmonary Arterial Hypertension — The First Selective IP-receptor Agonist Selexipag

Cardiovascular Therapy and Prevention (Russian Federation)
Cardiovascular MedicineCardiology
2019English

5-Ht3 Receptor Antagonism by Anpirtoline, a Mixed 5-Ht1 Receptor Agonist/5-Ht3 Receptor Antagonist

British Journal of Pharmacology
Pharmacology
1995English

The New Endothelin Receptor Antagonist Macitentan: Prospects for Therapy of Pulmonary Arterial Hypertension

Terapevticheskii Arkhiv
Internal MedicineEndocrinologyMetabolismDiabetes
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy